Table 1 Baseline characteristics of patients with type 2 diabetes
Variables | Intervention (n = 35) | Control (n = 36) | Pa |
|---|---|---|---|
Age, y | 50.1 ± 7.3 | 50.0 ± 7.6 | 0.96 |
Diabetes duration, y | 9.40 ± 7.0 | 8.11 ± 6.9 | 0.44 |
Gender | 0.89 | ||
Male, n (%) | 20 (57.1) | 20 (55.6) | |
Female, n (%) | 15 (42.9) | 16 (44.4) | |
Medications | |||
Metformin, n (%) | 30 (85.7) | 31 (86.1) | 0.96 |
Glibenclamide, n (%) | 11 (31.4) | 16 (44.4) | 0.25 |
Statins, n (%) | 3 (8.6) | 4 (11.1) | 0.70 |
Blood pressure lowering drugs, n (%) | 6 (17.2) | 5 (13.9) | 0.72 |
Height, cm | 164.94 ± 7.2 | 162.08 ± 11.29 | 0.20 |
Weight, kg | 73.69 ± 8.2 | 72.71 ± 10.5 | 0.66 |
BMI | 27.10 ± 2.6 | 27.66 ± 2.7 | 0.39 |
WC, cm | 91.75 ± 7.4 | 92.58 ± 8.5 | 0.66 |
HDL-c, mg/dL | 42.49 ± 7.9 | 45.83 ± 9.0 | 0.1 |
TG, mg/dL | 188.34 ± 81.8 | 159.89 ± 63.1 | 0.1 |
TC, mg/dL | 167.74 ± 33.8 | 184.03 ± 43.3 | 0.08 |
LDL-c, mg/dL | 95.86 ± 34.2 | 105.13 ± 48.7 | 0.36 |
LAP | 65.62 ± 36.5 | 55.74 ± 29.4 | 0.21 |
VAI | 3.29 ± 1.9 | 2.48 ± 1.2 | 0.04 |
CRI-I | 4.09 ± 1.0 | 4.17 ± 1.1 | 0.78 |
CRI-II | 2.35 ± 0.9 | 2.42 ± 1.2 | 0.79 |
AC | 3.09 ± 1.0 | 3.17 ± 1.1 | 0.78 |